JP4920163B2 - Ｉｉ型糖尿病およびｘ症候群の進行を防止するのに有用な鎮痙剤誘導体 - Google Patents

Ｉｉ型糖尿病およびｘ症候群の進行を防止するのに有用な鎮痙剤誘導体 Download PDF

Info

Publication number
JP4920163B2
JP4920163B2 JP2002508438A JP2002508438A JP4920163B2 JP 4920163 B2 JP4920163 B2 JP 4920163B2 JP 2002508438 A JP2002508438 A JP 2002508438A JP 2002508438 A JP2002508438 A JP 2002508438A JP 4920163 B2 JP4920163 B2 JP 4920163B2
Authority
JP
Japan
Prior art keywords
topiramate
formula
diabetes
mice
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002508438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004510700A (ja
JP2004510700A5 (enExample
Inventor
プラタ−サラマン・カルロス
クルーク・ジェフリー
Original Assignee
オーソーマクニール ファーマシューティカル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーソーマクニール ファーマシューティカル， インコーポレイテッド filed Critical オーソーマクニール ファーマシューティカル， インコーポレイテッド
Publication of JP2004510700A publication Critical patent/JP2004510700A/ja
Publication of JP2004510700A5 publication Critical patent/JP2004510700A5/ja
Application granted granted Critical
Publication of JP4920163B2 publication Critical patent/JP4920163B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002508438A 2000-07-07 2001-07-06 Ｉｉ型糖尿病およびｘ症候群の進行を防止するのに有用な鎮痙剤誘導体 Expired - Lifetime JP4920163B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21714100P 2000-07-07 2000-07-07
US60/217,141 2000-07-07
US27002201P 2001-02-20 2001-02-20
US60/270,022 2001-02-20
PCT/US2001/021404 WO2002003984A2 (en) 2000-07-07 2001-07-06 Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x

Publications (3)

Publication Number Publication Date
JP2004510700A JP2004510700A (ja) 2004-04-08
JP2004510700A5 JP2004510700A5 (enExample) 2012-02-02
JP4920163B2 true JP4920163B2 (ja) 2012-04-18

Family

ID=26911655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002508438A Expired - Lifetime JP4920163B2 (ja) 2000-07-07 2001-07-06 Ｉｉ型糖尿病およびｘ症候群の進行を防止するのに有用な鎮痙剤誘導体

Country Status (22)

Country Link
US (2) US6852701B2 (enExample)
EP (1) EP1309324B1 (enExample)
JP (1) JP4920163B2 (enExample)
CN (1) CN101404993A (enExample)
AR (1) AR032465A1 (enExample)
AT (1) ATE320805T1 (enExample)
AU (1) AU2001280486A1 (enExample)
BR (1) BR0112519A (enExample)
CA (1) CA2415093A1 (enExample)
DE (1) DE60118206T2 (enExample)
DK (1) DK1309324T3 (enExample)
ES (1) ES2260261T3 (enExample)
HU (1) HUP0302307A3 (enExample)
IL (1) IL153713A0 (enExample)
MX (1) MXPA03000136A (enExample)
MY (1) MY126897A (enExample)
NO (1) NO20030064L (enExample)
NZ (1) NZ523531A (enExample)
PL (1) PL365680A1 (enExample)
PT (1) PT1309324E (enExample)
RU (1) RU2268720C2 (enExample)
WO (1) WO2002003984A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
WO2004050081A1 (en) * 2002-12-02 2004-06-17 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP4912312B2 (ja) * 2004-08-24 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗痙攣薬として有用な新規なベンゾ−縮合ヘテロアリールスルファミド誘導体
CA2609185A1 (en) * 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
AU2007253814A1 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
ES2660170T3 (es) 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
WO2010008776A2 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
EP2829270B1 (en) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Joint product containing synephrine and topiramate
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000130A2 (en) * 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Anticonvulsant sulfamate derivatives useful in treating obesity
WO1999044581A2 (en) * 1998-03-04 1999-09-10 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical composition of topiramate
WO2000061139A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in reducing blood glucose levels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
NZ513643A (en) 1999-02-24 2005-04-29 Univ Cincinnati Use of sulfamate derivatives for treating impulse control disorders
AU4050100A (en) 1999-04-08 2000-11-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
US6191163B1 (en) * 1999-04-08 2001-02-20 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering lipids
WO2000076493A1 (en) 1999-06-14 2000-12-21 Thomas Najarian Combination therapy for effecting weight loss and treating obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000130A2 (en) * 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Anticonvulsant sulfamate derivatives useful in treating obesity
WO1999044581A2 (en) * 1998-03-04 1999-09-10 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical composition of topiramate
WO2000061139A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in reducing blood glucose levels

Also Published As

Publication number Publication date
CA2415093A1 (en) 2002-01-17
US6852701B2 (en) 2005-02-08
EP1309324B1 (en) 2006-03-22
NO20030064L (no) 2003-03-06
MY126897A (en) 2006-10-31
AR032465A1 (es) 2003-11-12
HUP0302307A3 (en) 2007-05-29
US20020037861A1 (en) 2002-03-28
ES2260261T3 (es) 2006-11-01
DE60118206D1 (de) 2006-05-11
MXPA03000136A (es) 2004-09-13
NO20030064D0 (no) 2003-01-06
DK1309324T3 (da) 2006-06-12
CN101404993A (zh) 2009-04-08
PL365680A1 (en) 2005-01-10
NZ523531A (en) 2005-07-29
JP2004510700A (ja) 2004-04-08
HUP0302307A2 (hu) 2003-10-28
AU2001280486A1 (en) 2002-01-21
WO2002003984A3 (en) 2003-03-06
PT1309324E (pt) 2006-06-30
US7109174B2 (en) 2006-09-19
WO2002003984A2 (en) 2002-01-17
RU2268720C2 (ru) 2006-01-27
BR0112519A (pt) 2004-03-30
EP1309324A2 (en) 2003-05-14
DE60118206T2 (de) 2006-12-14
IL153713A0 (en) 2003-07-06
ATE320805T1 (de) 2006-04-15
US20040209824A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
US6852701B2 (en) Anticonvulsant derivatives useful for preventing the development of Type II diabetes mellitus and Syndrome X
US20230285329A1 (en) Methods and Compositions for the Treatment of Steatosis-Associated Disorders
RU2214241C2 (ru) Способ лечения ожирения и способ индуцирования потери веса у млекопитающих
EP0660706B1 (en) Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol
US20040157785A1 (en) Combination therapy comprising anti-diabetic and anticonvulsant agents
CZ20023121A3 (cs) Farmaceutické prostředky pro léčení diabetických komplikací a neuropatie a jejich použití
JP7721447B2 (ja) ネコの糖尿病を管理する化合物
EP4342476A1 (en) Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozin
EP1148874B1 (en) Use of anticonvulsant derivatives for treating bulimia nervosa
EP1592417B1 (en) Combination of antidiabetic drugs
ZA200301044B (en) Anticonvulsant derivatives useful for preventing the development of Type II diabetes mellitus and Syndrome X.
KR20250076353A (ko) 글루콘산 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 비만 및 당뇨병의 예방, 개선 또는 치료용 조성물
WO2025101731A1 (en) Sglt1 inhibitors for use in the treatment of hepatic encephalopathy
KR20240143043A (ko) Pdh 억제제의 신경병증 치료 용도
Thampi Asymtomatic Cardiac Changes In Type 2 Diabetes Mellitus

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111124

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120110

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120201

R150 Certificate of patent or registration of utility model

Ref document number: 4920163

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term